Actelion (XSWX:ATLNE) FCF Margin % : 30.09% (As of Mar. 2017)

View and export this data going back to . Start your Free Trial

What is Actelion FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Actelion's Free Cash Flow for the three months ended in Mar. 2017 was CHF194 Mil. Actelion's Revenue for the three months ended in Mar. 2017 was CHF646 Mil. Therefore, Actelion's FCF Margin % for the quarter that ended in Mar. 2017 was 30.09%.

As of today, Actelion's current FCF Yield % is 3.03%.

The historical rank and industry rank for Actelion's FCF Margin % or its related term are showing as below:

XSWX:ATLNE' s FCF Margin % Range Over the Past 10 Years
Min: 0 Med: 0 Max: 35.94
Current: 35.94

During the past 13 years, the highest FCF Margin % of Actelion was 35.94%. The lowest was 0.00%. And the median was 0.00%.

XSWX:ATLNE's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -149.8 vs XSWX:ATLNE: 35.94

Actelion FCF Margin % Historical Data

The historical data trend for Actelion's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion FCF Margin % Chart

Actelion Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

FCF Margin %

Get a 7-Day Free Trial

30.84

31.61

6.61

30.01

35.65

Actelion Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
FCF Margin %	Get a 7-Day Free Trial															28.33	37.58	43.22	33.35	30.09

Competitive Comparison of Actelion's FCF Margin %

For the Biotechnology subindustry, Actelion's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actelion's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actelion's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Actelion's FCF Margin % falls into.

Actelion FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Actelion's FCF Margin for the fiscal year that ended in Dec. 2016 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2016 )	/	Revenue (A: Dec. 2016 )
	=	862.088	/	2417.938
	=	35.65 %

Actelion's FCF Margin for the quarter that ended in Mar. 2017 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2017 )	/	Revenue (Q: Mar. 2017 )
	=	194.434	/	646.253
	=	30.09 %

Actelion FCF Margin % Related Terms

Thank you for viewing the detailed overview of Actelion's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Actelion (XSWX:ATLNE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (XSWX:ATLNE) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.actelion.com

Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (XSWX:ATLNE) Headlines

No Headlines